Manipulating bone disease in inflammatory bowel disease patients

P. Miheller, William Gesztes, P. Lakatos

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Diagnostic and therapeutic recommendations of the actual guidelines regarding inflammatory bowel disease (IBD)-associated bone loss are based on the experiences from the general osteoporotic population. Moreover, the fracture, as an end point of the bone loss has a different relationship to the bone mineral density in these patients compared to the general population. In this review we aimed to review the literature of the novel therapeutic possibilities regarding IBD-related bone loss. Dual-energy X-ray absorptiometry measurement should be performed in the presence of a risk factor such as age above 50, postmenopausal state, low trauma bone fracture in the history, corticosteroid therapy for more than 3 months or signs of hypogonadism. Serum Vitamin D and calcium levels should be measured in all patients. Supplementation is definitely needed in case of low serum calcium or Vitamin D concentrations and in patients under corticosteroid induction therapy. Short-term use of bisphosphonates in case of steroid induction was proved to be efficacious in preventing bone loss, but recent approvals do not include these indications. As fluorides and hormone replacement therapy have considerable side effects, their use in the young generation is also not acceptable.

Original languageEnglish
Pages (from-to)296-303
Number of pages8
JournalAnnals of Gastroenterology
Volume26
Issue number4
Publication statusPublished - 2013

Fingerprint

Bone Diseases
Inflammatory Bowel Diseases
Bone and Bones
Vitamin D
Adrenal Cortex Hormones
Calcium
Hypogonadism
Bone Fractures
Hormone Replacement Therapy
Photon Absorptiometry
Diphosphonates
Therapeutics
Serum
Fluorides
Bone Density
Population
History
Steroids
Guidelines
Wounds and Injuries

Keywords

  • Bisphosphonates
  • Bone loss
  • Fluoride
  • Hormone replacement therapy
  • Inflammatory bowel disease
  • Vitamin D

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Manipulating bone disease in inflammatory bowel disease patients. / Miheller, P.; Gesztes, William; Lakatos, P.

In: Annals of Gastroenterology, Vol. 26, No. 4, 2013, p. 296-303.

Research output: Contribution to journalArticle

@article{8ad61a2b8b654efabdcccae9d8d68e02,
title = "Manipulating bone disease in inflammatory bowel disease patients",
abstract = "Diagnostic and therapeutic recommendations of the actual guidelines regarding inflammatory bowel disease (IBD)-associated bone loss are based on the experiences from the general osteoporotic population. Moreover, the fracture, as an end point of the bone loss has a different relationship to the bone mineral density in these patients compared to the general population. In this review we aimed to review the literature of the novel therapeutic possibilities regarding IBD-related bone loss. Dual-energy X-ray absorptiometry measurement should be performed in the presence of a risk factor such as age above 50, postmenopausal state, low trauma bone fracture in the history, corticosteroid therapy for more than 3 months or signs of hypogonadism. Serum Vitamin D and calcium levels should be measured in all patients. Supplementation is definitely needed in case of low serum calcium or Vitamin D concentrations and in patients under corticosteroid induction therapy. Short-term use of bisphosphonates in case of steroid induction was proved to be efficacious in preventing bone loss, but recent approvals do not include these indications. As fluorides and hormone replacement therapy have considerable side effects, their use in the young generation is also not acceptable.",
keywords = "Bisphosphonates, Bone loss, Fluoride, Hormone replacement therapy, Inflammatory bowel disease, Vitamin D",
author = "P. Miheller and William Gesztes and P. Lakatos",
year = "2013",
language = "English",
volume = "26",
pages = "296--303",
journal = "Annals of Gastroenterology",
issn = "1108-7471",
publisher = "Hellenic Society of Gastroenterology",
number = "4",

}

TY - JOUR

T1 - Manipulating bone disease in inflammatory bowel disease patients

AU - Miheller, P.

AU - Gesztes, William

AU - Lakatos, P.

PY - 2013

Y1 - 2013

N2 - Diagnostic and therapeutic recommendations of the actual guidelines regarding inflammatory bowel disease (IBD)-associated bone loss are based on the experiences from the general osteoporotic population. Moreover, the fracture, as an end point of the bone loss has a different relationship to the bone mineral density in these patients compared to the general population. In this review we aimed to review the literature of the novel therapeutic possibilities regarding IBD-related bone loss. Dual-energy X-ray absorptiometry measurement should be performed in the presence of a risk factor such as age above 50, postmenopausal state, low trauma bone fracture in the history, corticosteroid therapy for more than 3 months or signs of hypogonadism. Serum Vitamin D and calcium levels should be measured in all patients. Supplementation is definitely needed in case of low serum calcium or Vitamin D concentrations and in patients under corticosteroid induction therapy. Short-term use of bisphosphonates in case of steroid induction was proved to be efficacious in preventing bone loss, but recent approvals do not include these indications. As fluorides and hormone replacement therapy have considerable side effects, their use in the young generation is also not acceptable.

AB - Diagnostic and therapeutic recommendations of the actual guidelines regarding inflammatory bowel disease (IBD)-associated bone loss are based on the experiences from the general osteoporotic population. Moreover, the fracture, as an end point of the bone loss has a different relationship to the bone mineral density in these patients compared to the general population. In this review we aimed to review the literature of the novel therapeutic possibilities regarding IBD-related bone loss. Dual-energy X-ray absorptiometry measurement should be performed in the presence of a risk factor such as age above 50, postmenopausal state, low trauma bone fracture in the history, corticosteroid therapy for more than 3 months or signs of hypogonadism. Serum Vitamin D and calcium levels should be measured in all patients. Supplementation is definitely needed in case of low serum calcium or Vitamin D concentrations and in patients under corticosteroid induction therapy. Short-term use of bisphosphonates in case of steroid induction was proved to be efficacious in preventing bone loss, but recent approvals do not include these indications. As fluorides and hormone replacement therapy have considerable side effects, their use in the young generation is also not acceptable.

KW - Bisphosphonates

KW - Bone loss

KW - Fluoride

KW - Hormone replacement therapy

KW - Inflammatory bowel disease

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84884930765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884930765&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 296

EP - 303

JO - Annals of Gastroenterology

JF - Annals of Gastroenterology

SN - 1108-7471

IS - 4

ER -